The March 13 short interest data in top biotechs have been compared with the end of February figures, and across the board all the selected stocks have seen their short interest increase.
Deutsche Bank says that investors have misread the current instances floating around two leading biotech stocks, and they both should be bought now on any continuing weakness.
Thursday's top analyst upgrades and downgrades include Chesapeake Energy, eBay, Enterprise Products Partners, Gilead Sciences, Newmont Mining and Wynn Resorts.
Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.
24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with the mid-February figures. Across the board, all the selected stocks have seen…
With AT&T dropped from the Dow in favor of Apple, investors may be wondering which Dow stocks could get booted from the index next.
UBS reports that corporations are generating an incredible $1 trillion a year in cash, and the believe these five top companies will stay focused on returning capital to shareholders.
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Bought as a basket, these four companies could offer long-term investors a perfect compliment of stocks covering the health care sector.
Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid pipelines and, most importantly, earnings.
The stock market continues to act like an aging prize fighter, one that will not give up despite all the haymakers landed. In keeping with the bullish tone, insiders continue buying stock.
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Credit Suisse downgraded Gilead Sciences to Neutral and lowered its price target, citing increased competition for hepatitis C drugs.
Chris Lange Friday's top analyst upgrades, downgrades and initiations include Best Buy, Gilead Sciences, KeyCorp, National Bank of Greece, Pandora Media, Staples and Yelp.
Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a move follows Amgen.
